1Florida Alzheimer's Disease Research Center

1佛罗里达阿尔茨海默病研究中心

• 批准号: 10190771
• 负责人: Todd E Golde
• 金额: $ 298.72万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10190771
• 关键词: African American; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Amyloid; Autopsy; Biological Markers; Brain; Caring; Caucasians; Cognitive; Collaborations; Communities; Cultural Diversity; Data; Data Analyses; Data Set; Databases; Dementia; Diagnosis; Disease; Educational Activities; Enrollment; Environment; Epidemic; Etiology; European; Evaluation; Family; Florida; Fostering; Funding; Future; Genetic Variation; Goals; Grant; Health Professional; Hispanics; Impaired cognition; Incidence; Individual; Institution; International; Intervention; Knowledge; Language; Lewy Body Dementia; Linguistics; Longitudinal cohort; Longitudinal cohort study; Magnetic Resonance Imaging; Medical; Medical center; Minority Groups; Mission; Natural History; Neuropsychological Tests; Not Hispanic or Latino; Participant; Pathogenesis; Patients; Pilot Projects; Population; Population Heterogeneity; Positron-Emission Tomography; Publications; Research; Research Personnel; Resources; Risk Factors; Scanning; Science; Scientist; Specialized Center; Training; Translating; Underrepresented Minority; United States; United States National Institutes of Health; Universities; Vascular Diseases; Work; accurate diagnosis; base; career development; cognitive change; cohort; comorbidity; data portal; data sharing; disease heterogeneity; ethnic diversity; follow-up; human old age (65+); imaging study; improved; innovation; inter-institutional; member; novel; novel marker; racial and ethnic; racial diversity; ranpirnase; recruit; response; retention rate; skills; tool; training opportunity; web portal

With ~560,000 Alzheimer’s disease (AD) patients and >4 million residents >65 years old, Florida is, and will continue to be, an epicenter of the AD epidemic in the United States. The 1Florida ADRC is a collaboration between Florida institutions, including the University of Florida (UF), Mt. Sinai Medical Center in Miami Beach (MSMC), University of Miami (UM), Florida International University (FIU), and Florida Atlantic University (FAU). The 1Florida ADRC’s global mission is to work with other ADRCs and stakeholders in the AD field to help change the understanding of AD and related dementias (ADRDs) to a new reality in which ADRDs are more facilely and accurately diagnosed, more effectively treated, and ultimately preventable or curable. Much of what we know about the natural history of AD, risk factors for cognitive decline, and response to interventions has come from study of Caucasian populations, largely of European descent. Multiple studies suggest a higher incidence of dementia among Hispanics and other underrepresented minority populations (URM), but whether these findings are broadly generalizable is unclear. Our successful recruitment and evaluation of a majority Hispanic cohort has enabled us to begin to evaluate whether there are differences in ADRDs between Hispanics and non- Hispanics in South Florida. Enhancing our understanding of dementia in ethnically and racially diverse populations is a major theme of our ADRC that will be expanded to include African Americans. As we transition towards an ADRC potentially funded as a P30, we will leverage our successful institutional and investigator partnerships to further expand our recruitment and longitudinal follow up of participants with ethnic, linguistic, cultural, and genetic diversity, as well as comorbidities associated with AD (e.g., vascular disease, Lewy Body Dementia (LBD)). Our overall specific aims are to: 1) Elucidate novel markers for the earliest prodromal stages of cognitive impairment and identify predictors of decline in our ethnically and racially diverse participants, who present with no or varied comorbidities. These longitudinal cohort studies, biomarker studies, and neuropathological studies will help the field to better understand AD, comorbidities, and disease heterogeneity. 2) Enhance our institutional research environments and provide resources to foster a) unique training opportunities; b) career development; and c) novel and innovative research in ADRDs with a growing emphasis on cross-disciplinary team science and advanced data analysis approaches. 3) Provide data, research tools and biospecimens to, and interact with, a wide variety of stakeholders within and outside (e.g., NACC, NCRAD) of our collaborating institutional network. 4) Provide educational activities relevant to ADRDs to health professionals, those in training, and to lay community members, with the goals of improving knowledge, developing skills, and building stronger coalitions to deliver better diagnoses and care to patients and their families.

佛罗里达有大约56万阿尔茨海默病（AD）患者和超过400万65岁以上的居民， 仍然是美国AD流行病的中心。佛罗里达州ADRC是一个合作 之间的佛罗里达机构，包括佛罗里达大学（UF），山。迈阿密海滩的西奈医疗中心 （MSMC）、迈阿密大学（UM）、佛罗里达国际大学（FIU）和佛罗里达大西洋大学（FAU）。 佛罗里达州ADRC的全球使命是与其他ADRC和AD领域的利益相关者合作，帮助改变 对AD和相关痴呆症（ADRD）的理解，使其成为一个新的现实， 准确诊断，更有效地治疗，并最终预防或治愈。我们所知道的大部分 关于AD的自然史、认知能力下降的风险因素以及对干预措施的反应， 研究高加索人，主要是欧洲血统。多项研究表明， 西班牙裔和其他代表性不足的少数民族人口（URM）中的痴呆症，但这些发现是否 是否具有广泛的普遍性尚不清楚。我们成功招募和评估了大多数西班牙裔队列 使我们能够开始评估西班牙裔和非西班牙裔之间的ADRD是否存在差异。 南佛罗里达的西班牙裔。提高我们对不同种族和民族的痴呆症的理解 人口是我们ADRC的一个主要主题，将扩大到包括非洲裔美国人。因为我们已经过渡 对于一个可能作为P30资助的ADRC，我们将利用我们成功的机构和调查人员 伙伴关系，以进一步扩大我们的招聘和纵向跟进参与者的种族，语言， 文化和遗传多样性，以及与AD相关的合并症（例如，血管疾病，路易体 痴呆（LBD））。我们的总体具体目标是：1）阐明最早前驱期的新标志物 认知障碍，并确定我们的种族和种族多样化的参与者下降的预测因素， 没有或存在各种合并症。这些纵向队列研究、生物标志物研究和 神经病理学研究将有助于该领域更好地了解AD、合并症和疾病异质性。 2)加强我们的机构研究环境，并提供资源，以促进a）独特的培训 机会; B）职业发展;以及c）越来越重视ADRD的新颖和创新研究 跨学科团队科学和先进的数据分析方法。3)提供数据、研究工具和 生物标本，并与各种利益相关者内外（例如，NACC、NCRAD） 我们的合作机构网络。4)提供与ADRD相关的健康教育活动 专业人员，那些在培训，并奠定社区成员，以提高知识的目标， 发展技能，建立更强大的联盟，为患者及其家属提供更好的诊断和护理。 家庭